KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Shares Outstanding (Weighted Average) (2016 - 2025)

Emergent BioSolutions (EBS) has 12 years of Shares Outstanding (Weighted Average) data on record, last reported at $53.5 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 0.94% year-over-year to $53.5 million; the TTM value through Dec 2025 reached $53.5 million, up 0.94%, while the annual FY2025 figure was $53.5 million, 0.94% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $53.5 million in Q4 2025 per EBS's latest filing, up from $53.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $54.4 million in Q1 2025 and bottomed at $50.0 million in Q2 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $52.2 million, with a median of $52.5 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): decreased 6.54% in 2022, then increased 4.21% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $53.5 million in 2021, then decreased by 6.36% to $50.1 million in 2022, then grew by 2.2% to $51.2 million in 2023, then grew by 3.52% to $53.0 million in 2024, then increased by 0.94% to $53.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $53.5 million in Q4 2025, $53.2 million in Q3 2025, and $54.3 million in Q2 2025.